Autoimmune Market Forecast

Share:    

Autoimmune Market Forecast

Autoimmune Market Forecast to 2014 (TA223)

Overview :

Drive blockbuster revenue with autoimmune breakthroughs
Share:    

The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

Learn how brands and drug classes have fared: where they've succeeded - and failed

Show solid, objective evidence for your decision-making

Keep track of the competition

Get the latest on clinical trials

Uncover potential business development opportunities

Companies Included in Report

The report analyzes autoimmune portfolios at nine companies that are successful in the autoimmune market. Each company profile examines strategies and identifies strengths and weaknesses.

Abbott

Roche

Centacor (Johnson & Johnson)

Biogen Idec

Amgen

Pfizer

Schering-Plough (Merck)

Merck KGaA

Teva

Metrics Included in Report

Chapter 1: Autoimmune Indication Snapshots

This section provides historical context, possible causes, epidemiological data, treatment information and new developments for each of the following major autoimmune indications:

Rheumatoid arthritis

Psoriasis and psoriatic arthritis

Ulcerative colitis

Crohn's disease

Systemic lupus erythematosus and lupus nephritis

Chapters 2 and 3: Brand profiles for Biologic and Small Molecule Therapies

Organized by class, brand profiles include the following points:

Drug's current and projected competitive strength

Sales projection charts through 2014

Materiality charts

Clinical trial information

Patent/market exclusivity tables

Classes covered in the report:

TNF inhibitors

B-cell inhibitors

Interferon betas

Interleukin inhibitors

Immunomodulators

NSAIDs

5-ASAs

Antimetabolites

Corticosteroids

JAK inhibitors

Chapter 4: Autoimmune Drug Manufacturer Profiles

This chapter provides analysis of nine top autoimmune drug makers' portfolios. Company profiles include:

Ranking within market

Strengths analysis

Growth areas analysis

Key products breakdown

For more information kindly visit

http://www.bharatbook.com/detail.asp?id=100595&rt=Autoimmune-Market-Forecast.html

OR Contact us at

Bharat Book Bureau

207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Share:    

Phone : +91 22 2757 8668 / 2757 9438

Fax : +91 22 2757 9131

E-mail : info@bharatbook.com

Website : www.bharatbook.com

POST COMMENT

Make Sure You Understand Your Medicare Coverage Natural Ways To Increase Breast Size - Increase Size Of Boobs Without Surgery Bigger Breasts Without Surgery - Getting Larger Breasts Without Implants Natural Breast Enlargement Method - Enhance Your Breast Size Without Surgery Get Natural Breast Enhancement Without Surgery Medical insurance options in Florida Visitors Medical Insurance: Terms And Benefits Online Pharmacy: Best way To Buy Medicines Online Birth Control Pills for Women Autoimmune Disorders Causing Hair Loss How To Improve Breast Size Naturally Without Surgery Benefits from Medicare Supplement Insurance Online Training for Emergency Medical Technician Careers